Virax Biolabs Group Limited (VRAX) Stock
VRAX Key Statistics
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
CEO: James Foster. Company website
VRAX — Frequently Asked Questions
What is the VRAX stock price today?
Virax Biolabs Group Limited (VRAX) trades at $3.88, up 40.58% on the day, as of Sep 20, 2026 15:01 UTC.
What is Virax Biolabs Group Limited's market cap?
Virax Biolabs Group Limited has a market capitalisation of $16.85M, calculated from the live VRAX share price and shares outstanding.
What is the P/E ratio of VRAX?
VRAX has no meaningful price-to-earnings ratio: Virax Biolabs Group Limited lost $1.25 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Virax Biolabs Group Limited make?
Virax Biolabs Group Limited generated revenue of $2,986.00 over the trailing twelve months, which puts the stock at 5,641.93 times sales.
What is the 52-week range for VRAX?
VRAX has traded between $0.10 and $13.34 over the past 52 weeks, and the last price is 70.9% below that high.
Is Virax Biolabs Group Limited profitable?
No. Virax Biolabs Group Limited is loss-making, with a net margin of -9,999.99% over the trailing twelve months.
What is the analyst price target for VRAX?
Wall Street analysts rate VRAX Buy, with an average price target of $1.00, 74.2% below the current price.
What sector is Virax Biolabs Group Limited in?
Virax Biolabs Group Limited is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in GB .
Who is the CEO of Virax Biolabs Group Limited?
James Foster is the chief executive of Virax Biolabs Group Limited, which employs 17 people.
Where can I track VRAX in real time?
QFI Terminal shows VRAX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See VRAX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open VRAX in Terminal See plans